文献速递类风湿关节炎

TNF抑制剂治疗与类风湿关节炎患者10年后手骨关节炎进展风险降低相关

TNF inhibitor treatment is associated with a lower risk of hand osteoarthritis progression in rheumatoid arthritis patients after 10 years.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

在BeSt研究262例近期起病类风湿关节炎患者中,基线及10年随访时评估手骨关节炎。58%患者接受TNF抑制剂治疗,中位疗程42个月。TNF抑制剂治疗每增加1个月,远端指间关节手骨关节炎进展的相对风险降低(RR 0.987,95%CI 0.978,0.996),近端指间关节无此关联。

要点

  • TNF抑制剂治疗每增加1个月,远端指间关节手骨关节炎进展风险RR为0.987(95%CI 0.978,0.996)。
  • 近端指间关节手骨关节炎进展与TNF抑制剂治疗时长无显著关联。
  • TNF抑制剂治疗时长对 incident 手骨关节炎无影响。

核心结论

  • TNF抑制剂治疗与10年后远端指间关节影像学手骨关节炎进展风险降低相关,近端指间关节无此关联。
  • 效应量虽小,但这些结果为TNF-α参与手骨关节炎发病机制提供了证据。

研究设计与样本

  • 来自BeSt研究的262例近期起病类风湿关节炎患者,平均年龄52岁,66%为女性。
  • 基线及10年随访时,采用OARSI图谱(0-3分,总分0-54)评估远端指间关节和近端指间关节骨赘,并采用Kellgren-Lawrence评分(0-4分,总分0-72)评估。
  • 每3个月访视评估TNF抑制剂治疗,采用广义线性模型和广义估计方程分别在患者水平和关节水平分析关联。

主要发现

  • 58%患者接受TNF抑制剂治疗,中位疗程42个月。
  • 基于OARSI骨赘评分,143例(55%)患者基线时任一指间关节存在手骨关节炎。
  • 患者水平:TNF抑制剂治疗时长对 incident 手骨关节炎无影响;每增加1个月TNF抑制剂治疗,远端指间关节手骨关节炎进展RR为0.987(95%CI 0.978,0.996),近端指间关节无此关联。
  • 关节水平:远端指间关节手骨关节炎进展RR为0.996(95%CI 0.991,1.000),近端指间关节无此关联。
  • Kellgren-Lawrence评分分析结果与骨赘评分结果相当。

关键数值与推荐

  • 远端指间关节手骨关节炎进展(患者水平):每增加1个月TNF抑制剂治疗,RR 0.987(95%CI 0.978,0.996)。
  • 远端指间关节手骨关节炎进展(关节水平):RR 0.996(95%CI 0.991,1.000)。
  • 近端指间关节手骨关节炎进展:患者水平及关节水平均无显著关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effect of TNF inhibitors (TNFis) on incidental and progressive hand OA in recent-onset RA patients after a 10 year follow-up. METHODS: Radiographs of 262 RA patients (mean age 52 years, 66% women) from the BeSt study were scored for osteophytes in DIP/PIP joints using the Osteoarthritis Research Society International atlas (0-3; summed score 0-54) and according to the Kellgren-Lawrence (KL) score (0-4; summed score 0-72) at baseline and 10 year follow-up. TNFi treatment was assessed on visits every 3 months. Associations between TNFi treatment and hand OA were analysed on the patient and joint level using generalized linear models and generalized estimating equations, respectively. RESULTS: Fifty-eight percent of the patients were treated with TNFi, with a median duration of 42 months. A total of 143 patients (55%) had hand OA in any IP joint at baseline based on the Osteoarthritis Research Society International osteophyte score. On the patient level, TNFi treatment duration did not affect incidental hand OA. However, every month of TNFi treatment resulted in a reduced relative risk (RR) of hand OA progression in DIP joints [relative risk (RR) 0.987 (95% CI 0.978, 0.996)] but not in PIP joints. On the joint level, the effect on hand OA progression was observed in DIP joints [RR 0.996 (95% CI 0.991, 1.000)] but not in PIP joints. The results from the KL score analyses were comparable to the osteophyte score. CONCLUSION: TNFi treatment was associated with a reduced risk on radiographic hand OA progression in DIP joints but not in PIP joints after 10 years. Although the effect sizes are small, these results provide evidence for influence of TNF-α in hand OA pathogenesis.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Loef M, Kroon FPB, Bergstra SA, et al. TNF inhibitor treatment is associated with a lower risk of hand osteoarthritis progression in rheumatoid arthritis patients after 10 years. Rheumatology (Oxford). 2018. PMID: 29471377. doi:10.1093/rheumatology/key016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。